48
Participants
Start Date
May 15, 2024
Primary Completion Date
December 10, 2026
Study Completion Date
July 1, 2032
[177Lu]Lu-NeoB
Radiopharmaceutical solution for infusion
[68Ga]Ga-NeoB
Either provided as Kit for the radiopharmaceutical preparation of \[68Ga\]Ga-NeoB or as ready to use radiopharmaceutical solution for injection
Temozolomide
Capsules/ lyophilized powder in single-dose vial for reconstitution.
RECRUITING
Memorial Sloan Kettering Cancer Ctr, New York
RECRUITING
Novartis Investigative Site, Marseille
RECRUITING
Novartis Investigative Site, Granada
RECRUITING
Novartis Investigative Site, Rostock
RECRUITING
Novartis Investigative Site, Dijon
RECRUITING
Novartis Investigative Site, Madrid
RECRUITING
Novartis Investigative Site, Madrid
RECRUITING
Mayo Clinic Jacksonville, Jacksonville
RECRUITING
Novartis Investigative Site, Reggio Emilia
RECRUITING
Novartis Investigative Site, Essen
RECRUITING
Novartis Investigative Site, Cologne
RECRUITING
University of Colorado Denver, Aurora
RECRUITING
Novartis Investigative Site, München
RECRUITING
Uni of Utah Huntsman Cancer Inst, Salt Lake City
RECRUITING
University of California LA, Los Angeles
RECRUITING
Novartis Investigative Site, Jerusalem
RECRUITING
Dana Farber Cancer Institute, Boston
RECRUITING
Univ Hosp Cleveland Medical Center, Cleveland
RECRUITING
Novartis Investigative Site, Porto
RECRUITING
Novartis Investigative Site, L'Hospitalet de Llobregat
RECRUITING
Novartis Investigative Site, Badalona
RECRUITING
Novartis Investigative Site, Barcelona
RECRUITING
Novartis Investigative Site, Liverpool
Lead Sponsor
Novartis Pharmaceuticals
INDUSTRY